Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Financial Officer | June 18, 2026 | June 23, 2026 |
| LogicBio Therapeutics, Inc.LOGC · Entity 122292 | Chief Financial Officer | March 01, 2022 | March 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance share unitsSEC Table II · derivative / convertible security | Direct | 9,000 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Disposed 3,000 · Balance 9,000 F1: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 3,000 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 3,000 · Balance 3,000 F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
LogicBio Therapeutics, Inc.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2032-03-01 | Direct | 112,000 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 112,000 · Balance 112,000 F1: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan. F2: The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan.
F2: The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 26, 2023 Filed Sep 28, 2023 20:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 7,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000133 · wk-form4_1695931360.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 499 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,597 | $28.36 | $45,290.92 |
DisclosureSEC source: 0001439222-23-000101 · wk-form4_1688155416.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,783 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 5,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000101 · wk-form4_1688155416.xml · derivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,380 Underlying: Common stock · 5,380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000101 · wk-form4_1688155416.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 22,000 | $0.00 Strike: $25.01 | $0.00 |
DisclosureSEC source: 0001439222-23-000050 · wf-form4_167787761251341.xml · derivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common stock · 22,000 shares Expires 2033-03-01 F3 · derivative.exercise_date: This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000050 · wf-form4_167787761251341.xml · derivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 22,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000089 · wf-form4_166439584185254.xml · derivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,417 Underlying: Common stock · 22,417 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 118,390 | $0.00 Strike: $27.88 | $0.00 |
DisclosureSEC source: 0001439222-22-000089 · wf-form4_166439584185254.xml · derivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,390 Underlying: Common stock · 118,390 shares Expires 2032-09-26 F1 · derivative.exercise_date: This option was granted on September 26, 2022. The shares underlying this option vest as to 25% of the underlying shares on September 26, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 18:05 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 112,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-22-015795 · doc4.xml · derivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2032-03-01 F1 · shares: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan. F2 · derivative.exercise_date: The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 18:36 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | Tax withholdingCommon Stock | 2,175 | $2.01 | $4,371.75 |
DisclosureSEC source: 0001209191-22-003250 · doc4.xml · nonDerivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,764 F2 · price: This sale was made automatically by the Company to cover tax withholding obligations in connection with the vesting and settlement of the RSUs reported in the row above. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.03, inclusive. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 18:36 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | Exercise / conversionRestricted Stock Units · Derivative | 5,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003250 · doc4.xml · derivative · entry 3 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,939 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company"). F3 · derivative.exercise_date: These RSUs, which represent 100% of the RSUs granted to the Reporting Person that were previously reported for the Reporting Person on a Form 4 filed on January 13, 2021, vested on January 11, 2022, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan. F3 · derivative.expiration_date: These RSUs, which represent 100% of the RSUs granted to the Reporting Person that were previously reported for the Reporting Person on a Form 4 filed on January 13, 2021, vested on January 11, 2022, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 18:36 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | Exercise / conversionCommon Stock | 5,939 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003250 · doc4.xml · nonDerivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company"). Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 19:00 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 78,000 | $0.00 Strike: $7.76 | $0.00 |
DisclosureSEC source: 0001209191-21-014476 · doc4.xml · derivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2031-02-23 F1 · derivative.exercise_date: 25% vests on 01/11/2022 and the remainder vests in equal monthly installments over the next 36 months. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 19:10 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantRestricted Stock Units · Derivative | 5,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003473 · doc4.xml · derivative · entry 2 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,939 Underlying: Common Stock · 5,939 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of LogicBio Therapeutics Inc. (the "Company") common stock. F3 · derivative.exercise_date: The RSUs will fully vest on January 11, 2022, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan; provided, that if the reporting person's employment is terminated by the Company without "cause" or by the reporting person for "good reason" (as defined in the reporting person's employment agreement) prior to January 11, 2022, all such RSUs will vest on the date of termination. F3 · derivative.expiration_date: The RSUs will fully vest on January 11, 2022, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan; provided, that if the reporting person's employment is terminated by the Company without "cause" or by the reporting person for "good reason" (as defined in the reporting person's employment agreement) prior to January 11, 2022, all such RSUs will vest on the date of termination. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 19:10 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 195,000 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-21-003473 · doc4.xml · derivative · entry 1 Jones Cecilia · CIK 0001840056 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2031-01-11 F1 · derivative.exercise_date: 25% vests on 01/11/2022 and the remainder vests in equal monthly installments over the next 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.